Two biotechs target dry eye disease after Novartis' Xiidra p...

The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis.

Boehringer bags CHMP backing for Ofev in rare lung disease

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lu...

Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.